Sanofi Price to Book Ratio 2010-2023 | SNY
Historical price to book ratio values for Sanofi (SNY) over the last 10 years. The current price to book ratio for Sanofi as of April 25, 2024 is 1.55.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Sanofi Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2024-04-26 |
49.13 |
|
1.54 |
| 2023-12-31 |
49.73 |
$31.81 |
1.56 |
| 2023-09-30 |
53.64 |
|
0.00 |
| 2023-06-30 |
53.90 |
$31.50 |
1.71 |
| 2023-03-31 |
52.44 |
|
0.00 |
| 2022-12-31 |
46.67 |
$31.40 |
1.49 |
| 2022-09-30 |
36.64 |
|
0.00 |
| 2022-06-30 |
48.21 |
|
0.00 |
| 2019-09-30 |
40.17 |
|
0.00 |
| 2019-03-31 |
36.85 |
|
0.00 |
| 2018-03-31 |
31.84 |
|
0.00 |
| 2017-12-31 |
34.16 |
$26.26 |
1.30 |
| 2017-09-30 |
39.55 |
|
0.00 |
| 2017-06-30 |
38.06 |
$25.22 |
1.51 |
| 2017-03-31 |
34.77 |
|
0.00 |
| 2016-12-31 |
31.07 |
$24.72 |
1.26 |
| 2016-09-30 |
29.34 |
|
0.00 |
| 2016-06-30 |
32.16 |
$23.85 |
1.35 |
| 2016-03-31 |
29.60 |
|
0.00 |
| 2015-09-30 |
34.98 |
|
0.00 |
| 2015-06-30 |
36.50 |
$23.95 |
1.52 |
| 2014-06-30 |
37.95 |
|
0.00 |
| 2013-06-30 |
35.49 |
|
0.00 |
| 2012-06-30 |
25.15 |
|
0.00 |
| 2012-03-31 |
24.65 |
|
0.00 |
| 2011-12-31 |
23.24 |
|
0.00 |
| 2011-09-30 |
20.86 |
|
0.00 |
| 2011-06-30 |
25.55 |
|
0.00 |
| 2011-03-31 |
21.65 |
|
0.00 |
| 2010-12-31 |
19.81 |
|
0.00 |
| 2010-09-30 |
20.44 |
|
0.00 |
| 2010-06-30 |
18.48 |
|
0.00 |
| 2010-03-31 |
22.15 |
|
0.00 |
| 2009-12-31 |
23.29 |
|
0.00 |
| 2009-09-30 |
21.91 |
|
0.00 |
| 2009-06-30 |
17.49 |
|
0.00 |
| 2022-03-31 |
47.88 |
|
0.00 |
| 2009-03-31 |
15.70 |
|
0.00 |
| 2021-09-30 |
44.96 |
|
0.00 |
| 2021-03-31 |
44.44 |
|
0.00 |
| 2020-09-30 |
45.08 |
|
0.00 |
| 2020-03-31 |
37.91 |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$124.861B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
